Toward the treatment and prevention of alzheimer's disease: Rational strategies and recent progress

Annual Review of Medicine

Volumn 64, Issue , 2013, Pages 367-383

  Gandy, Sam ^a   DeKosky, Steven T ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

amyloidosis; cognitive decline; dementia; memory disorder; neurodegeneration

Indexed keywords

AMYLOID BETA PROTEIN; BAPINEUZUMAB; BEXAROTENE; BIOLOGICAL MARKER; CARBON 11; CRENEZUMAB; DIMEBON; DONEPEZIL; FLORBETABEN; FLORBETAPIR F 18; FLUORINE 18; FLUTEMETAMOL F 18; GALANTAMINE; HUPERZINE A; IMATINIB; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; PHENOL; PIBAXIZINE; RESVERATROL; RIVASTIGMINE; SECRETASE; SEMAGACESTAT;

ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; BRAIN CORTEX; BRAIN DISEASE; BRAIN REGION; CATALYSIS; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEMENTIA; DIET; DISEASE COURSE; EPIDEMIC; FRONTOTEMPORAL DEMENTIA; GENOME; GINKGO BILOBA; HUMAN; LIFESTYLE; META ANALYSIS (TOPIC); NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RISK ASSESSMENT; SYMPTOM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; BRAIN; DNA; HUMANS; IMMUNOLOGIC FACTORS; INCIDENCE; MUTATION; PRACTICE GUIDELINES AS TOPIC; WORLD HEALTH;

EID: 84873026509     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-092611-084441     Document Type: Article

References (94)

1. Yaffe K, Middleton LE, Lui LY, et al. 2011. Mild cognitive impairment, dementia, and their subtypes in oldest old women. Arch. Neurol. 68:631-36
2. Bowen DM, Smith CB, Davison AN. 1973. Molecular changes in senile dementia. Brain 96:849-56
3. Bertram L, Lill CM, Tanzi RE. 2010. The genetics of Alzheimer disease: back to the future. Neuron 68:270-81
4. Glenner GG. 1980. Amyloid deposits and amyloidosis: the beta-fibrilloses (second of two parts). N. Engl. J. Med. 302:1333-43
5. Masters CL, Simms G, Weinman NA, et al. 1985. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 82:4245-9
6. Corder EH, Saunders AM, Strittmatter WJ, et al. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-23
7. Quintero-Monzon O, Martin MM, Fernandez MA, et al. 2011. Dissociation between the processivity and total activity of γ-secretase: implications for the mechanism of Alzheimer's disease-causing presenilin mutations. Biochemistry 50:9023-35
8. De Strooper B. 2007. Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 8:141-46
9. Holmes O, Paturi S, Ye W, et al. 2012. Effects of membrane lipids on the activity and processivity of purified γ-secretase. Biochemistry 51:3565-75
10. Shepardson NE, Shankar GM, Selkoe DJ. 2011. Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch. Neurol. 68:1239-44
11. Shepardson NE, Shankar GM, Selkoe DJ. 2011. Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch. Neurol. 68:1385-92
12. Rogaeva E, Meng Y, Lee JH, et al. 2007. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 39:168-77
13. Pottier C, Hannequin D, Coutant S, et al. 2012. High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Mol. Psychiatry 17:875-79
14. Lane RF, Raines SM, Steele JW, et al. 2010. Diabetes-associated SorCS1 regulates Alzheimer's amyloidbeta metabolism: evidence for involvement of SorL1 and the retromer complex. J. Neurosci. 30:13110-15
15. Clee SM, Yandell BS, Schueler KM, et al. 2006. Positional cloning of Sorcs1, a type 2 diabetes quantitative trait locus. Nat. Genet. 38:688-93
16. Fjorback AW, SeamanM, Gustafsen C, et al. 2012. Retromer binds the FANSHY sorting motif in SorLA to regulate amyloid precursor protein sorting and processing. J. Neurosci. 32:1467-80
17. Small SA, Gandy S. 2006. Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis. Neuron 52:15-31
18. Klunk WE, Engler H, Nordberg A, et al. 2004. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55:306-19
19. Weiner MW, Veitch DP, Aisen PS, et al. 2012. Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 8 (Suppl. 1):S1-68
20. Fagan AM, Mintun MA, Mach RH, et al. 2006. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann. Neurol. 59:512-19
21. DeMeyer G, Shapiro F, Vanderstichele H, et al. 2010. Diagnosis- independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch. Neurol. 67:949-56
22. Cairns NJ, Ikonomovic MD, Benzinger T, et al. 2009. Absence of Pittsburgh Compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch. Neurol. 66:1557-62
23. Ikonomovic MD, Abrahamson EE, Price JC, et al. 2012. Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. Acta Neuropathol. 123:433-47
24. Schöll M, Wall A, Thordardottir S, et al. 2012. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology 79:229-36
25. Gandy S, Simon AJ, Steele JW, et al. 2010. Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann. Neurol. 68:220-30
26. Lublin AL, Gandy S. 2010. Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer's disease. Mt. Sinai J. Med. 77:43-49
27. Clark CM, Pontecorvo MJ, Beach TG, et al. 2012. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol. 11:669-78
28. Maarouf CL, Daugs ID, Kokjohn TA, et al. 2011. Alzheimer's disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging. PLoS ONE 6:e27291
29. Stern Y, Albert S, Tang MX, et al. 1999. Rate of memory decline in AD is related to education and occupation: cognitive reserve? Neurology 53:1942-47
30. Dubois B, Feldman HH, Jacova C, et al. 2010. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 9:1118-27
31. Gabel MJ, Foster NL, Heidebrink JL, et al. 2010. Validation of consensus panel diagnosis in dementia. Arch. Neurol. 67:1506-12
32. McKhann GM, Knopman DS, Chertkow H, et al. 2011. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7:263-69
33. DeKosky ST, Carrillo MC, Phelps C, et al. 2011. Revision of the criteria for Alzheimer's disease: a symposium. Alzheimers Dement. 7:e1-12
34. Bertram L, McQueen MB, Mullin K, et al. 2007. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 39(1):17-23
35. Yang DS, Small DH, Seydel U, et al. 1999. Apolipoprotein E promotes the binding and uptake of betaamyloid into Chinese hamster ovary cells in an isoform-specific manner. Neuroscience 90:1217-26
36. Holtzman DM, Bales KR, Tenkova T, et al. 2000. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 97:2892-97
37. Deane R, Sagare A, Hamm K, et al. 2008. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Investig. 118:4002-13
38. Kim J, Basak JM, Holtzman DM. 2009. The role of apolipoprotein E in Alzheimer's disease. Neuron 63:287-303
39. Castellano JM, Kim J, Stewart FR, et al. 2011. Human apoE isoforms differentially regulate brain amyloid- βpeptide clearance. Sci. Transl. Med. 3:89ra57
40. Wexler EM, Rosen E, Lu D, et al. 2011. Genome-wide analysis of a Wnt1-regulated transcriptional network implicates neurodegenerative pathways. Sci. Signal. 4:ra65
41. Choi SH, Tanzi RE. 2012. iPSCs to the rescue in Alzheimer's research. Cell Stem Cell 10:235-36
42. Qiang L, Fujita R, Yamashita T, et al. 2011. Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons. Cell 146:359-71
43. Sproul AA, Jacob S, NestorMW, et al. 2012. Development of an induced pluripotent stem cell Alzheimer's disease model using PSEN1 mutant fibroblasts. Alzheimers Dement. 8:P310
44. DeKosky ST, Ikonomovic MD, Gandy S. 2010. Traumatic brain injury: football, warfare, and long-term effects. N. Engl. J. Med. 363:1293-96
45. Costanza A, WeberK, Gandy S, et al. 2011. Review: contact sport-related chronic traumatic encephalopathy in the elderly: clinical expression and structural substrates. Neuropathol. Appl. Neurobiol. 37:570-84
46. Omalu BI, DeKosky ST, Minster RL, et al. 2005. Chronic traumatic encephalopathy in a National Football League player. Neurosurgery 57:128-34; discuss. 128-34
47. Omalu BI, Fitzsimmons RP, Hammers J, et al. 2010. Chronic traumatic encephalopathy in a professional American wrestler. J. Forensic Nurs. 6:130-36
48. Kim N, Zimmerman M, Lipton R, et al. 2011. Making soccer safer for the brain: DTI-defined exposure thresholds for white matter injury due to soccer heading. Presented at Radiolog. Soc.North Am. Sci. Assem. Annu.Meet., 97th, McCormick Place. http://rsna2011.rsna.org/search/event-display.cfm?em-id= 11001570
49. Omalu B, Hammers JL, Bailes J, et al. 2011. Chronic traumatic encephalopathy in an Iraqi war veteran with posttraumatic stress disorder who committed suicide. Neurosurg. Focus 31:E3
50. Mayeux R, Ottman R, Maestre G, et al. 1995. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology 45:555-57
51. Jordan BD, Relkin NR, Ravdin LD, et al. 1997. Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing. JAMA 278:136-40
52. Rebeck GW, Reiter JS, Strickland DK, et al. 1993. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 11:575-80
53. Geschwind D, Karrim J, Nelson SF, et al. 1998. The apolipoprotein E epsilon4 allele is not a significant risk factor for frontotemporal dementia. Ann. Neurol. 44:134-38
54. Ikonomovic MD, Uryu K, Abrahamson EE, et al. 2004. Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury. Exp. Neurol. 190(1):192-203
55. Gandy S, DeKosky ST. 2012. APOE ε4 status and traumatic brain injury on the gridiron or the battlefield. Sci. Transl. Med. 4:134ed4
56. Clavaguera F, Bolmont T, Crowther RA, et al. 2009. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11:909-13
57. Liu L, Drouet V, WuJW, et al. 2012. Trans-synaptic spread of tau pathology in vivo. PLoS ONE 7:e31302
58. de Calignon A, Polydoro M, Suárez-Calvet M, et al. 2012. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73:685-97
59. Jones EM, Surewicz WK. 2005. Fibril conformation as the basis of species- and strain-dependent seeding specificity of mammalian prion amyloids. Cell 121:63-72
60. Rinne JO, Brooks DJ, Rossor MN, et al. 2010. 11C-PiBPETassessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebocontrolled, ascending-dose study. Lancet Neurol. 9:363-72
61. Gandy S. 2010. Testing the amyloid hypothesis of Alzheimer's disease in vivo. Lancet Neurol. 9:333-35
62. Sperling RA, Jack CR Jr, Aisen PS. 2011. Testing the right target and right drug at the right stage. Sci. Transl. Med. 3:111cm33
63. Schenk D, Barbour R, Dunn W, et al. 1999. Immunization with amyloid-beta attenuates Alzheimerdisease- like pathology in the PDAPP mouse. Nature 400:173-77
64. Bateman RJ, Xiong C, Benzinger TLS, et al. 2012. Clinical and biomarker changes in dominantly inherited Alzheimers disease. N. Eng. J. Med. 367:795-804
65. Salloway S, Sperling R, Gilman S, et al. 2009. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73:2061-70
66. Kaufer D, Gandy S. 2009. APOE ε4 and bapineuzumab: infusing pharmacogenomics into Alzheimer disease therapeutics. Neurology 73:2052-53
67. Relkin NR, Szabo P, Adamiak B, et al. 2009. 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging 30:1728-36
68. Relkin N, Bettger L, Tsakanikas D, et al. 2012. Three-year follow up on the IVIG for Alzheimer's Phase II Study. Presented at Alzheimer's Assoc. Int. Conf., Vancouver
69. Szabo P, Relkin N, Weksler ME. 2008. Natural human antibodies to amyloid beta peptide. Autoimmun. Rev. 7:415-20
70. Kaneko Y, Nimmerjahn F, Ravetch JV. 2006. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313:670-73
71. Atwal JK, Chen Y, Chiu C, et al. 2011. A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Sci. Transl. Med. 3:84ra43
72. Santuccione AC, Merlini M, Shetty A, et al. 2012. Active vaccination with ankyrin G reduces β-amyloid pathology in APP transgenic mice. Mol. Psychiatry. Epub ahead of print; doi: 10.1038/mp.2012.70
73. Jonsson KT, Atwal JK, Steinberg S, et al. 2012. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488:96-99
74. He G, LuoW, Li P, et al. 2010. Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature 467:95-98
75. Netzer WJ, Dou F, Cai D, et al. 2003. Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc. Natl. Acad. Sci. USA 100:12444-49
76. Cramer PE, Cirrito JR, Wesson DW, et al. 2012. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 335:1503-6
77. Mouchiroud L, Molin L, Dallière N, et al. 2010. Life span extension by resveratrol, rapamycin, and metformin: the promise of dietary restriction mimetics for an healthy aging. Biofactors 36:377-82
78. Snitz BE, O'Meara ES, Carlson MC, et al. 2009. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA 302:2663-70
79. Bachurin S, Bukatina E, Lermontova N, et al. 2001. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann. N.Y. Acad. Sci. 939:425-35
80. Doody RS, Gavrilova SI, Sano M, et al. 2008. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 372:207-15
81. Steele JW, Lachenmayer ML, Ju S, et al. 2012. Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model. Mol. Psychiatry. Epub ahead of print; doi:1038/mp.2012.106/mp.2012.106
82. Steele JW, Ju S, Lachenmayer ML, et al. 2012. Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain. Mol. Psychiatry. Epub ahead of print; doi: 1038/mp:2012.115
83. James BD, Bennett DA, Boyle PA, et al. 2012. Dementia from Alzheimer disease and mixed pathologies in the oldest old. JAMA 307:1798-800
84. Scheltens P, Twisk JW, Blesa R, et al. 2012. Efficacy of souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. J. Alzheimers Dis. 31(1):225-36
85. Rolland Y, Pillard F, Klapouszczak A, et al. 2007. Exercise program for nursing home residents with Alzheimer's disease: a 1-year randomized, controlled trial. J. Am. Geriatr. Soc. 55:158-65
86. Venturelli M, Scarsini R, Schena F. 2011. Six-month walking program changes cognitive and ADL performance in patients with Alzheimer. Am. J. Alzheimers Dis. Other Dement. 26:381-88
87. Head D, Bugg JM, Goate AM, et al. 2012. Exercise engagement as a moderator of the effects of APOE genotype on amyloid deposition. Arch. Neurol. 69:636-43
88. García-Mesa Y, López-Ramos JC, Giménez-Llort L, et al. 2011. Physical exercise protects against Alzheimer's disease in 3xTg-AD mice. J. Alzheimers Dis. 24:421-54
89. Kempermann G, van Praag H, Gage FH. 2000. Activity-dependent regulation of neuronal plasticity and self repair. Prog. Brain Res. 127:35-48
90. He C, Bassik MC, Moresi V, et al. 2012. Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature 481:511-15
91. Nagahara AH, Merrill DA, Coppola G, et al. 2009. Long-term reversal of cholinergic neuronal decline in aged non-human primates by lentiviral NGF gene delivery. Exp. Neurol. 215:153-59
92. Gandy S. 2011. Perspective: prevention is better than cure. Nature 475:S15
93. Klunk WE, Price JC, Mathis CA, et al. 2007. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J. Neurosci. 27:6174-84
94. Lowenthal J, Hull SC, Pearson SD. 2012. The ethics of early evidence. N. Engl. J. Med. 367:488-90